AUSTRALIAN PRODUCT INFORMATION

Neo-Mercazole®
Carbimazole
Tablet

1 NAME OF THE MEDICINE

Carbimazole

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each Neo-Mercazole tablet contains 5 mg of carbimazole as the active ingredient.
Excipients with known effect: lactose monohydrate and sucrose.
For the full list of excipients, see Section 6.1 List of excipients.

3 PHARMACEUTICAL FORM

Neo-Mercazole 5 mg tablets are pale pink, circular biconvex tablet embossed with Neo 5 on one side and plain on the other side.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS


4.2 DOSE AND METHOD OF ADMINISTRATION

It is customary to begin therapy with a dosage that will fairly quickly control the thyrotoxicosis and render the patient euthyroid, and later to reduce this.

The tablets are for oral administration.

Adults

Usual initial dosages
Mild cases, 15 to 20 mg/day in divided doses; moderate cases, 30 mg/day in divided doses; severe cases, 40 to 45 mg (up to 60 mg) /day in divided doses and should be titrated against
thyroid function until the patient is euthyroid in order to reduce the risk of over-treatment and resultant hypothyroidism.

If large stores of hormone are present, as in nodular goitre, response to Neo-Mercazole may be delayed for several weeks or months, whereas in severe thyrotoxicosis, when very little hormone is stored, improvement may be detected within three to four days.

**Maintenance dosage**

When symptoms are controlled the dosage should be reduced to a maintenance level, which will usually be between 10 and 15 mg daily.

Experience has shown there is a wide variation of sensitivity to the medicine from time to time in a particular patient. Serial thyroid function monitoring is recommended, together with appropriate dosage modification in order to maintain a euthyroid state. For this reason, patients should be seen monthly for the first year; and thereafter at 3 or 6 monthly intervals. Once a remission has been secured, maintenance dosage should be continued for at least 12 months, and up to 2 years of treatment may be required.

If thyroidectomy is intended, it can be carried out once the euthyroid state is achieved with Neo-Mercazole, which is then discontinued.

**Changeover from thiouracils**

When treatment with one of the thiouracils is replaced by Neo-Mercazole therapy, 50 mg of methylthiouracil or propylthiouracil can be taken as equivalent to 5 mg of Neo-Mercazole.

**Delayed response to Neo-Mercazole therapy**

If no relief is obtained within three months, the possible causes are: patients have failed to take their Neo-Mercazole (this is the most common cause); previous iodine therapy which has resulted in an increased hormone store within the gland; inadequate dosage of Neo-Mercazole.

**Preparation of thyrotoxic patients for surgery**

Neo-Mercazole is prescribed prior to thyroidectomy and should then be given in sufficient dosage and for long enough to render the patient euthyroid. It should be continued up to the time of operation but should be prescribed together with iodide during the last 2 weeks.

**Elderly**

No special dosage regimen is required, but care should be taken to observe the contraindications and warnings as it has been reported that the risk of a fatal outcome to neutrophil dyscrasia may be greater in the elderly (aged 65 or over).

**4.3 CONTRAINDICATIONS**

- Neo-Mercazole is contraindicated in patients with a previous history of adverse reactions to carbimazole or to any of the excipients in the composition.
- Retrosternal goitre.
- Serious pre-existing haematological conditions.
- Severe hepatic insufficiency.
Patients with a history of acute pancreatitis after administration of carbimazole or its active metabolite thiamazole.

Neo-Mercazole should be given with caution if there is any degree of tracheal obstruction, as high dosage may increase thyroid enlargement and aggravate obstructive symptoms.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Neo-Mercazole should only be administered if hyperthyroidism has been confirmed by laboratory tests. Dosage should be titrated against thyroid function until the patient is euthyroid in order to reduce the risk of over-treatment and resultant hypothyroidism. Serial thyroid function monitoring is recommended together with appropriate dosage modification in order to maintain a euthyroid state (see Section 4.2 Dosage and method of administration).

As fatal cases of agranulocytosis with carbimazole have been reported and early treatment of agranulocytosis is essential, it is important that patients should always be warned about the onset of sore throats, bruising or bleeding, mouth ulcers, fever, malaise or other symptoms which might suggest bone marrow depression and should be instructed to stop the medicine and to seek medical advice immediately. In such patients, blood cell counts should be performed immediately, particularly where there is any clinical evidence of infection. Early withdrawal of the medicine will increase the chance of complete recovery.

Rare cases of pancytopenia/aplastic anaemia, and very rare cases of haemolytic anaemia and thrombocytopaenia have been reported (see Section 4.8 Adverse effects).

Neo-Mercazole should be stopped temporarily at the time of administration of radio-iodine.

Patients unable to comply with the instructions for use or who cannot be monitored regularly should not be treated with Neo-Mercazole.

Regular full blood count checks should be carried out in patients who may be confused or have a poor memory.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Precautions should be taken in patients with intrathoracic goitre, which may worsen during initial treatment with Neo-Mercazole. Tracheal obstruction may occur due to intrathoracic goitre.

There have been post-marketing reports of acute pancreatitis in patients receiving carbimazole or its active metabolite thiamazole. In case of acute pancreatitis, carbimazole should be discontinued immediately. Carbimazole must not be given to patients with a history of acute pancreatitis after administration of carbimazole or its active metabolite thiamazole. Re-exposure may result in recurrence of acute pancreatitis, with decreased time to onset.

WARNINGS: Cases of vasculitis resulting in severe complications have been reported in patients receiving carbimazole and methimazole therapy. These cases of vasculitis include: leukocytoclastic cutaneous vasculitis, acute kidney injury and glomerulonephritis, alveolar/pulmonary haemorrhage, CNS vasculitis, and neuropathy. Most cases were associated with anti-neutrophilic cytoplasmic antibodies (ANCA)-positive vasculitis. In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids,
immunosuppressant therapy, and plasmapheresis. If vasculitis is suspected, discontinue therapy and initiate appropriate intervention.

**Women of childbearing potential and pregnancy**

Women of childbearing potential have to use effective contraceptive measures during treatment.

The use of carbimazole in non-pregnant women of childbearing potential should be based on individual risk/benefit assessment (see Section 4.6 Fertility, pregnancy and lactation, Use in pregnancy).

The use of carbimazole in pregnant women must be based on the individual benefit/risk assessment. If carbimazole is used during pregnancy, the lowest effective dose without additional administration of thyroid hormones should be administered. Close maternal, foetal and neonatal monitoring is warranted (see Section 4.6 Fertility, pregnancy and lactation, Use in pregnancy).

**Use in hepatic impairment**

Following the onset of any signs and symptoms of hepatic disorder (pain in the upper abdomen, anorexia, general pruritus) in patients, the medicine should be stopped and liver function tests performed immediately.

Neo-Mercazole should be used with caution in patients with mild-moderate hepatic insufficiency. If abnormal liver function is discovered, the treatment should be stopped. The half-life may be prolonged due to the liver disorder.

**Use in the elderly**

No data available.

**Paediatric use**

No data available.

**Effects on laboratory tests**

No data available.

### 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Little is known about interactions. There is a risk of cross-allergy between carbimazole, thiamazole and propylthiouracil.

Particular care is required in case of concurrent administration of medicines capable of inducing agranulocytosis.

Since carbimazole is a vitamin K antagonist, the effect of anticoagulants could be intensified. An accurate control with regards to the anticoagulant dosage is required as hyperthyroid patients receiving treatment with carbimazole become euthyroid; additional monitoring of prothrombin time/international normalised ratio (PT/INR) should be considered, especially before surgical procedures. Carbimazole administration may itself, rarely, result in hypoprothrombinaemia, which may increase the risk of haemorrhagic events.

The serum levels of theophylline can increase and toxicity may develop if hyperthyroidic patients are treated with antithyroid medicines without reducing the theophylline dosage.
Co-administration of prednisolone and carbimazole may result in increased clearance of prednisolone.

Carbimazole may inhibit the metabolism of erythromycin, leading to reduced clearance of erythromycin.

Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid; a reduced dosage of digitalis glycosides may be needed.

Hyperthyroidism may cause an increased clearance of beta-adrenergic blockers with a high extraction ratio. A dose reduction of beta blockers may be needed when a hyperthyroid patient becomes euthyroid.

Interaction studies have not been performed in paediatric patients.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility
There is no information on impairment of fertility following treatment with carbimazole.

Use in pregnancy (Category C)
Antithyroid agents may cause congenital goitre by inhibiting thyroxine synthesis in the foetus. During pregnancy these products should therefore only be used after carefully weighing the mother's needs against the risk to the foetus.

Studies have shown that the incidence of congenital malformations is greater in the children of mothers whose hyperthyroidism has remained untreated than in those who have been treated with carbimazole. However, very rare cases of congenital malformations have been observed following the use of carbimazole or its active metabolite methimazole during pregnancy. Cases of renal, skull, cardiovascular congenital defects, exomphalos, gastrointestinal malformation, umbilical malformations and duodenal atresia have been reported. A causal relationship of these malformations, especially choanal atresia and aplasia cutis congenital, to transplacental exposure to carbimazole and methimazole cannot be excluded. Therefore carbimazole should be used in pregnancy only when propylthiouracil is not suitable (see Section 4.4 Special warnings and precautions for use).

The basal metabolic rate is raised during pregnancy and the dosage of Neo-Mercazole must be adjusted accordingly. The smallest dose compatible with rendering the patient symptom free should be employed. The dosage during the last 3 months of pregnancy should, if possible, not exceed 15 mg twice daily.

Neo-Mercazole should be discontinued 3 to 4 weeks before delivery and a course of iodine should be substituted. The danger of producing hypothyroid babies as a result of low dosage antithyroid therapy during pregnancy appears to have been grossly exaggerated.

Hyperthyroidism in pregnant women should be adequately treated to prevent serious maternal and foetal complications.

Carbimazole is able to cross the human placenta.

Based on human experience from epidemiological studies and spontaneous reporting, carbimazole is suspected to cause congenital malformations when administered during pregnancy, particularly in the first trimester of pregnancy and at high doses.
Reported malformations include aplasia cutis congenita, craniofacial malformations (choanal atresia; facial dysmorphism), exomphalos, oesophageal atresia, omphalo-mesenteric duct anomaly, and ventricular septal defect.

Carbimazole must only be administered during pregnancy after a strict individual benefit/risk assessment and only at the lowest effective dose without additional administration of thyroid hormones. If carbimazole is used during pregnancy, close maternal, foetal and neonatal monitoring is recommended (see Section 4.4 Special warnings and precautions for use).

Women of childbearing potential

Women of childbearing potential have to use effective contraceptive measures during treatment (see Section 4.4 Special warnings and precautions for use).

Use in lactation

Carbimazole and related medicines cross the placenta and are concentrated in the breast milk. Infants should not be breastfed by mothers taking carbimazole.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

All toxic reactions to carbimazole occurred within 8 weeks of starting treatment, and there was no reaction in patients who received 20 mg or less of carbimazole per day. The most common minor side effects are nausea, headache, arthralgia and mild gastric distress. Mild skin rashes and pruritus can occur and these often respond to antihistamines without discontinuation of the medicine.

Adverse reactions are listed according to frequency, starting with the most frequent, and according to the following classification:

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common</td>
<td>≥ 1/10</td>
</tr>
<tr>
<td>Common</td>
<td>≥ 1/100, &lt; 1/10</td>
</tr>
<tr>
<td>Uncommon</td>
<td>≥ 1/1,000, &lt; 1/100</td>
</tr>
<tr>
<td>Rare</td>
<td>≥ 1/10,000, &lt; 1/1,000</td>
</tr>
<tr>
<td>Very rare</td>
<td>&lt; 1/10,000</td>
</tr>
<tr>
<td>Not known</td>
<td>Cannot be estimated from the available data</td>
</tr>
</tbody>
</table>

Blood and lymphatic system disorders

Of the major toxic reactions to carbimazole, bone marrow depression including neutropaenia, eosinophilia, leukopaenia and agranulocytosis are the most serious. Fatalities with carbimazole-induced agranulocytosis have been reported.

Rare: pancytopenia/aplastic anaemia.

Very rare: haemolytic anaemia, thrombocytopenia.

Patients should be warned about the onset of sore throats, bruising or bleeding, mouth ulcers, fever, and malaise (see Section 4.4 Special warnings and precautions for use).
Immune system disorders
Angioedema and multi-system hypersensitivity can cause liver, lung and renal effects. There are reports of vasculitis, often associated with the presence of anti-neutrophilic cytoplasmic antibodies (ANCA), resulting in severe complications (see Section 4.4 Special warnings and precautions for use).

Endocrine disorders
Not known: insulin autoimmune syndrome (with significant reduction in blood glucose levels).

Nervous system disorders
Headache, neuritis.

Vascular disorders
Bleeding.

Gastrointestinal system disorders
Nausea, mild gastric distress, loss of sense of taste.
Not known: acute pancreatitis.

Hepatobiliary disorders
Hepatic disorders including abnormal liver function tests, hepatitis, cholestatic hepatitis, cholestatic jaundice and most commonly jaundice, have been reported; in these cases carbimazole should be withdrawn.

Skin and subcutaneous tissue disorders
Skin rash, pruritus, urticaria, hair loss.
Severe cutaneous hypersensitivity reactions have been reported in both adults and paediatric patients, including generalised dermatitis and Stevens-Johnson syndrome (very rare).

Musculoskeletal and connective tissue disorders
Arthralgia.
Isolated cases of myopathy were reported in patients complaining from myalgia. Monitoring of creatine phosphokinase (CPK) levels is recommended in these instances.

General disorders and administration site conditions
Fever, malaise.

Injury, poisoning and procedural complications
Not known: bruising.

Reporting suspected adverse effects
Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.
4.9 OVERDOSE

Symptoms
The principle manifestations of poisoning are skin rash and leukopaenia. Acute poisoning has not been reported.

Treatment
Treat toxic neuropathy by physiotherapy.

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of action
Neo-Mercazole is an anti-thyroid agent.

Neo-Mercazole is believed to exert its antithyroid effect by 'blocking' the organic binding of iodine through inhibition of the iodination of tyrosine. It is also thought to have some action on peroxidase which is required as a catalyst in the synthesis of thyroxine by the thyroid gland. It does not affect the uptake of iodine by the thyroid gland and this is of vital importance in the treatment of thyrotoxicosis with radioactive iodine or with a combination of radiiodine and Neo-Mercazole, and also in preparation of patients for operation.

Clinical trials
No data available.

5.2 PHARMACOKINETIC PROPERTIES

Absorption
Carbimazole is rapidly absorbed from the gastrointestinal tract.

Metabolism
Carbimazole is completely and rapidly metabolised to methimazole and it is the latter that is responsible for the antithyroid activity of carbimazole. The mean peak plasma concentration of methimazole is reported to occur one hour after a single dose of carbimazole. The plasma half-life of methimazole is reported as between 3 and 6 hours.

Excretion
Most of an orally administered dose of carbimazole is excreted in the urine. Less than 12% may be excreted as unchanged methimazole.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity
No data available.
6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Neo-Mercazole contains lactose monohydrate, sucrose, maize starch, magnesium stearate, purified talc, acacia, iron oxide red and gelatin.

6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the ARTG. The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 25°C. Protect from moisture.

6.5 NATURE AND CONTENTS OF CONTAINER

Neo-Mercazole is available in a bottle of 100 tablets.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES

Chemical structure

\[
\begin{array}{c}
\text{O} \\
\text{C} \\
\text{H}_3
\end{array}
\]
The chemical name for carbimazole is ethyl 3-methyl-2-thioxo-4-imidazoline-1-carboxylate.

Molecular formula: \( \text{C}_7\text{H}_{10}\text{N}_2\text{O}_2\text{S} \)
Molecular weight: 186.2

Carbimazole is a white or yellowish-white crystalline powder, slightly soluble in water, soluble in alcohol and in acetone.

**CAS number**
22232-54-8

---

**7 MEDICINE SCHEDULE (POISONS STANDARD)**

Schedule 4 - Prescription Only Medicine

---

**8 SPONSOR**

Amdipharm Mercury (Australia) Pty Ltd
Level 9, 76 Berry Street
North Sydney NSW 2060

Ph: 1800 627 680

---

**9 DATE OF FIRST APPROVAL**

23 May 2012

---

**10 DATE OF REVISION**

14 June 2019

Amdipharm Mercury (Australia) Pty Ltd is licensed to use the trademark Neo-Mercazole

---

**SUMMARY TABLE OF CHANGES**

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>All sections</td>
<td>PI re-formatted in line with TGA approved form for Product Information</td>
</tr>
<tr>
<td>2 and 6.1</td>
<td>Lactose updated to lactose monohydrate to align with current Australian Approved Name</td>
</tr>
<tr>
<td>4.3, 4.4 and 4.8</td>
<td>Addition of contraindication, precautions and adverse effect related to pancreatitis</td>
</tr>
<tr>
<td>Section</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
</tr>
<tr>
<td>4.4 and 4.6</td>
<td>Addition of precautions and warnings (new information on the known risk of birth defects and neonatal disorders in case of exposure during pregnancy)</td>
</tr>
<tr>
<td>4.4 and 4.8</td>
<td>Addition of warning and adverse effect related to vasculitis</td>
</tr>
</tbody>
</table>